Sarikapan Wilailak

Sarikapan Wilailak

Auto-generated profile, based on publicly available information

Sarikapan Wilailak

Department of Obstetrics and Gynecology, Faculty of Medicine Ramathibodi Hospital Mahidol University Bangkok Thailand

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2021 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Open access
PDF file
SWSarikapan Wilailak
Sarikapan Wilailak
MKMalika Kengsakul
Malika Kengsakul
SKSean Kehoe
Sean Kehoe
In 2020, more than 600 000 women were diagnosed with cervical cancer and 342 000 women died worldwide. Without comprehensive control, rates of cervical cancer incidence and mortality are expected to worsen. In 2020, the World Health Organization adopted the global strategy to eliminate cervical cancer to the threshold of four cases per 100 000 women within the 21st century, using a triple pillar intervention strategy comprising 90% of girls fully vaccinated by the age of 15 years, 70% of women screened by the age of 35 years and again by 45 years, and 90% of women with precancer treated and 90% of women with invasive cancer managed. In countries with high cervical cancer incidence, a tremendous effort will be needed to overcome the challenges. This article discusses the efforts in place to accelerate achievement of this ambitious goal.

1 January 2015 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
SWSarikapan Wilailak
Sarikapan Wilailak
KCKaren Kl Chan
Karen Kl Chan
CCChi-An Chen
Chi-An Chen
JNJoo-Hyun Nam
Joo-Hyun Nam
KOKazunori Ochiai
Kazunori Ochiai
WSWalfrido W Sumpaico
Walfrido W Sumpaico
Wilailak S, et al. J Gynecol Oncol. 2015 Jan;26(1):46-53. http://dx.doi.org/10.3802/jgo.2015.26.1.46

1 January 2011 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
SWSarikapan Wilailak
Sarikapan Wilailak
ALArb-Aroon Lertkhachonsuk
Arb-Aroon Lertkhachonsuk
NLNawaporn Lohacharoenvanich
Nawaporn Lohacharoenvanich
SLSuteera Chukkul Luengsukcharoen
Suteera Chukkul Luengsukcharoen
MJManmana Jirajaras
Manmana Jirajaras
SSSuwannee Sirilerttrakul
Suwannee Sirilerttrakul
Wilailak S, et al. J Gynecol Oncol. 2011 Jun;22(2):103-109. http://dx.doi.org/10.3802/jgo.2011.22.2.103

4 September 2025 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Open access
SWSarikapan Wilailak
Sarikapan Wilailak
MKMalika Kengsakul
Malika Kengsakul
SKSean Kehoe
Sean Kehoe
Cervical cancer remains a major health burden, particularly in low‐ and middle‐income countries, despite being one of the most preventable cancers. WHO's 90–70–90 targets aim to eliminate cervical cancer globally by 2030. These targets include 90% of girls fully vaccinated with the HPV vaccine by the age of 15 years, 70% of women screened using a high‐performance test by the age of 35 years and again by 45 years, and 90% of women with cervical disease receiving appropriate treatment. Achieving these goals requires coordinated national efforts to strengthen health systems, ensure equitable access to care, and integrate cervical cancer control into broader health policies. This review outlines key strategic approaches, including the transition from conventional screening methods to HPV‐based screening, the adoption of innovative triage techniques, the implementation of single‐dose HPV vaccination, and the integration of primary treatment with palliative care. The strategy places strong emphasis on addressing health inequities, enhancing monitoring systems, and fostering partnerships between governments, non‐governmental organizations, and the private sector. With concerted global and national action, the elimination of cervical cancer is not only a possibility but an imminent reality.

1 January 2016 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
SWSarikapan Wilailak
Sarikapan Wilailak
NLNuttapong Lertchaipattanakul
Nuttapong Lertchaipattanakul
Wilailak S, et al. J Gynecol Oncol. 2016 Oct;27(6):e65. https://doi.org/10.3802/jgo.2016.27.e65

24 July 2025 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Open access
SNSurabhi Nanda
Surabhi Nanda
MNMelanie Nana
Melanie Nana
LNLong Nguyen‐Hoang
Long Nguyen‐Hoang
Sumaiya AdamSumaiya Adam
Sumaiya Adam
FMFionnuala McAuliffe
Fionnuala McAuliffe
LPLiona C. Poon
Liona C. Poon
Cancer during pregnancy is relatively rare. The incidence is underestimated due to the lack of international registries covering both high‐income and low‐ and middle‐income countries, and is expected to rise with increasing maternal age and increasing global adoption of cell‐free DNA testing for aneuploidy. Physiological changes during pregnancy often make the diagnosis challenging and delayed. Lack of experience and knowledge about this condition may also contribute to late diagnosis, suboptimal management, and occasionally inadvertent fetal and/or maternal harm. The principles of cancer management in pregnancy for most cancer types do not differ significantly from the non‐pregnant population. The impact of investigations for diagnosis and staging, risks of surgery, systemic chemotherapy, and/or radiotherapy on fetal well‐being and preterm birth need to be considered for treatment and management planning, in addition to maternal wishes. Working in a multidisciplinary setting, ideally with medical and radiation oncologists, surgeons, radiologists, cancer specialist nurses, geneticists, psychologists, teratologists, and clinical pharmacologists, obstetricians, obstetric physicians, neonatologists, and experienced nursing and midwifery staff helps provide optimal care for the woman. This best practice advice aims to provide recommendations on the diagnosis and management of cancer in pregnancy, which can be adopted in all resource settings.